In December, Congress passed a bipartisan law to boost federal medical research spending and to ease the approval of new drugs. In a panel discussion, experts at the Harvard T.H. Chan School of Public Health talked about its pros and cons, including whether it will be funded, and whether the relaxed drug approval guidelines are too easy.
A study by Harvard Medical School faculty members at Brigham and Women’s Hospital is exploring the health benefits of cocoa in a massive, 18,000-person study that may provide answers hinted at in smaller studies.
Cancer patients have new weapons on their side, provided by targeted drug therapy and, more recently, immune therapy. Now, the recent discovery of large numbers of noncoding RNA that are active in disease provides a new opportunity to both understand and fight cancer, according to Pier Paolo Pandolfi, professor at Harvard Medical School and director of the Cancer Center and Cancer Research Institute at Beth Israel Deaconess Medical Center.
Restoring the cancer-killing zeal of T cells is being seen as one of the most successful new approaches to cancer treatment in nearly a decade, although researchers note it has shown effectiveness in only about a quarter of cases.
A Harvard Chan School study suggests that relaxing current U.S. guidelines could provide greater health benefits with less harm and for less money in women who are vaccinated against human papillomavirus.
Chronic myelogenous leukemia (CML) is a slowly progressing type of blood cancer that develops in the bone marrow. Researchers discovered that CML stem cells die in response to inhibition of a protein called Ezh2. Drugs that target the protein are currently being tested in clinical trials for other cancers.
Harvard Medical School Professor William G. Kaelin Jr. was named the winner of the 2016 Lasker Award for Medical Research, America’s most prestigious biomedical award. He was honored for his work in the root causes of cancer.
The economic crisis of 2008-10, and the rise in unemployment that accompanied it, was associated with more than 260,000 excess cancer-related ...
An analysis of data from two long-term epidemiologic studies has found that regular use of aspirin significantly reduces the overall risk of cancer, an effect that primarily reflects a lower risk of colorectal cancer and other tumors of the gastrointestinal tract.
Children with acute lymphoblastic leukemia who live in high-poverty areas are substantially more likely to suffer early relapse than other patients, according to a new study.
A large new study of twins has found that a person whose twin is diagnosed with cancer stands an increased risk of also developing a form of cancer.
A study from Brigham and Women’s Hospital offers a new view of how cancer cells extend their reach, co-opting and transforming normal cells through “metastatic hijacking.” The researchers also found that in preclinical models, pharmacological intervention can prevent this from occurring.
A research team led by Martin Nowak has developed a model that captures both the shape and speed of tumor growth.
A team of scientists has engineered a form of the genome-editing protein Cas9 that can be controlled by a small molecule and offers improved DNA specificity.
A new study by investigators at Dana-Farber Cancer Institute demonstrates that vitamin D can protect some people with colorectal cancer by perking up the immune system’s vigilance against tumor cells.
Harvard-affiliated researchers have provided a see-through zebrafish and enhanced imaging that offer the first direct glimpse of how blood stem cells take root in the body to generate blood.
Harvard researchers have uncovered an easily detectable, “premalignant” state in the blood that significantly increases the likelihood that an individual will go on to develop blood cancers such as leukemia, lymphoma, or myelodysplastic syndrome.
A new genetic test developed by Harvard Medical School physicians at the Dana-Farber/Brigham and Women’s Cancer Center checks cells of leukemia and other blood cancers for 95 genetic mutations, providing a quick genetic profile that physicians can use to make treatment decisions.
People who have had colonoscopy or sigmoidoscopy to remove low-risk colorectal polyps may have no greater risk of dying from colon cancer than the general ...
In St. Louis, Missouri, Delmar Boulevard marks a sharp dividing line between the poor, predominately African American neighborhood to the north and a more ...
New research raises the prospect of more effective treatments for cachexia, a profound wasting of fat and muscle that occurs in about half of all cancer patients, increasing their risk of death. Harvard Professor Bruce Spiegelman demonstrated that symptoms of cachexia in mice improved when given an antibody that blocked the effects of a protein secreted by the tumor cells.
A team of researchers led by David J. Mooney, Robert P. Pinkas Family Professor of Bioengineering at the Harvard School of Engineering and Applied Sciences, has identified a possible mechanism by which normal cells turn malignant in mammary epithelial tissues, those frequently involved in breast cancer.
Fraternal twins Rosh and Roshan Sethi have shared much of their lives, including at Yale as undergraduates and sharing an apartment while enrolled at Harvard Medical School. Now preparing to graduate, they’re anticipating diverging careers, with Roshan exploring radiation oncology and Rosh head and neck surgery.
A newly discovered molecule may play a role in controlling both asthma-induced airway muscle thickening and tumor growth—and manipulating it may lead to ...
Investigators at Harvard-affiliated Massachusetts General Hospital (MGH) may have found a way to solve a problem that has plagued ligand-mimicking integrin inhibitors, a group of drugs that have the potential to treat conditions ranging from heart attacks to cancer metastasis.
A flexible work environment that enables staff to make time for physical activity appears to reduce cancer risk in middle-aged workers, according to ...
More than half of new cancer cases occur in low- and middle-income countries, as do nearly two-thirds of cancer deaths. Experts at a global oncology ...
The idea that the wave of diabetes, heart disease, and cancer breaking over the world is largely the result of wealth and inactivity is not only wrong, it’s counterproductive, says a Harvard research fellow who recently founded a nonprofit organization to fight disease.
Targeted nanotherapy is the wave of the medical future, according to Omid Farokhzad, a Harvard Medical School and Brigham and Women’s Hospital researcher who has two nanoparticle-based therapies in clinical trials and a slew of ideas for new ways to put the tiny capsules to work for human health.
A cross-disciplinary team of Harvard scientists, engineers, and clinicians announced Sept. 6 that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.
Harvard Professor Martin Nowak and Ivana Bozic, a postdoctoral fellow in mathematics, show that, under certain conditions, using two drugs in a “targeted therapy” — a treatment approach designed to interrupt cancer’s ability to grow and spread — could effectively cure nearly all cancers.
Michael A. Cianfrocco, a postdoctoral fellow in molecular and cellular biology, has been named a fellow by the Damon Runyon Cancer Research Foundation.
Harvard Stem Cell Institute researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity.
U.S. Rep. Eric I. Cantor, the House majority leader, embraced immigration reform, education changes, and medical research funding during a speech at the Harvard Kennedy School.
The amount of added sugars in soda and other sweetened beverages needs to be regulated, according to a Washington, D.C.-based nutrition advocacy group—and ...
Students at the Harvard School of Public Health are joining forces to draw attention to World Cancer Day on Feb. 4, organizing a symposium of experts to talk about the problem and collecting signatures for a declaration of cancer-related global health priorities.
Researchers have found that young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy.
Medical experts are coming to see cancer not as a disease of cells or even of genes, but as an “organismal disease,” Siddhartha Mukherjee, author of the Pulitzer Prize–winning cancer history “The Emperor of All Maladies,” told a Harvard Medical School audience on Oct. 11.
Researchers at Harvard-affiliated Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT used new technology to explore a 19-year-old theory, discovering what may be an Achilles’ heel for cancer cells: essential genes disrupted in the process of becoming cancerous that can be attacked further with drug therapy.
A team of researchers led by James G. Anderson, the Philip S. Weld Professor of Atmospheric Chemistry, warns that a newly discovered connection between climate change and depletion of the ozone layer over the U.S. could allow more damaging ultraviolet (UV) radiation to reach the Earth’s surface, leading to increased incidence of skin cancer.
Paul Farmer, chair of Harvard Medical School’s Department of Global Health and Social Medicine and co-founder of Partners In Health, announced the opening of Butaro Cancer Center of Excellence, which will serve as the first national cancer referral facility in rural Rwanda.
Professor Martin Nowak is one of several co-authors of a paper, published in Nature on June 28,that outlines a new approach to cancer treatment that could make many cancers manageable, if not curable, by overcoming resistance to certain drug treatments.
Harvard researchers have found that although tailored drugs can eradicate melanoma cells in the lab, they often produce only partial, temporary responses in patients. Researchers have now learned that normal cells that reside within the tumor, part of the tumor microenvironment, may supply factors that help cancer cells grow and survive despite the presence of anti-cancer drugs.
HMS faculty Kenneth Anderson, Paul Richardson, and Alfred Goldberg are three of four researchers being honored for their research and development of a pioneering cancer drug.
A fond look back at the memorable events of Harvard's 375th year.
Red Sox-themed fundraiser nets $11,700 for the Jimmy Fund.
The American Association for Cancer Research (AACR) presented Alan D. D'Andrea with the 52nd Annual AACR G.H.A. Clowes Memorial Award for his work in understanding cancer survival and progression.
A new study led by researchers at the Harvard School of Engineering and Applied Sciences and Massachusetts General Hospital has found that normalizing blood vessels within tumors, which improves the delivery of standard chemotherapy drugs, can actually block the delivery of larger nanotherapy molecules.
Harvard’s 25th annual Daffodil Days campaign to help raise money for the American Cancer Society is under way through March 1, with gifts scheduled for delivery on March 19.
Harvard researchers have been at the forefront of many battles against devastating diseases, leading pivotal breakthroughs against scourges from 1800 to the present.